Safety and Preliminary Efficacy of ATG-017 Monotherapy in Advanced Solid Tumors and Hematological Malignancies (ERASER)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04305249 |
|
Recruitment Status :
Recruiting
First Posted : March 12, 2020
Last Update Posted : August 4, 2022
|
Sponsor:
Antengene Therapeutics Limited
Information provided by (Responsible Party):
Antengene Corporation ( Antengene Therapeutics Limited )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase I, multi-center, open-label study of ATG-017 administered orally, alone in patients with advanced solid tumors and hematological malignancies. The study design includes a Dose Escalation Phase and Dose Expansion Phase.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Solid Tumor Hematological Malignancy | Drug: ATG-017 | Phase 1 |
The dose escalation of ATG 017 with intensive safety monitoring to ensure the safety of the patients with solid tumors (solid tumors group) and hematological malignancies (hematological malignancies group) harbouring activating alterations in the RAS-MAPK pathway. Dose Expansion Phase will begin at the defined maximum tolerated dose (MTD) and/or biologically effective dose and/or other dose, in order to further evaluate the safety, tolerability and PDx of ATG 017. Patients with solid tumors or hematological malignancies harbouring activating alterations in the RAS-MAPK pathway will be enrolled.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 60 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies |
| Actual Study Start Date : | August 15, 2020 |
| Estimated Primary Completion Date : | May 20, 2023 |
| Estimated Study Completion Date : | August 20, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ATG-017
ATG-017 will be administered orally on an empty stomach QD in the first cohort of solid tumors group and BID 12 hours apart (no food or drink other than water for 2 hours prior to, and for 1 hour after study treatment administration) in other cohorts. All doses of ATG-017 should be taken at approximately the same time each day. Patients will receive study treatment in 21-day cycles.
|
Drug: ATG-017
Dosing will begin at 5 mg once a day (QD) ATG-017 as starting dose. A cycle of study treatment will be defined as 21 days.
Other Name: AZD0364 hemi-adipic acid |
Primary Outcome Measures :
- AEs/SAEs [ Time Frame: 18 months ]Toxicity will be graded according to the NCI CTCAE, Version 5.0.
Secondary Outcome Measures :
- Plasma concentrations [ Time Frame: 18 months ]Venous blood samples for determination of total concentrations of ATG 017 in plasma to characterise the PK profile of ATG-017 for a particular dose level
- Overall Response Rate (ORR) [ Time Frame: 18 months ]To determine the overall response rate according to RECIST1.1, Chenson 2014, IWG 2003 and 2006
- DOR [ Time Frame: 18 months ]Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented
- Progression-Free Survival (PFS) [ Time Frame: 18 months ]The time from the first dose date until disease progression or death from any cause
Other Outcome Measures:
- Level of phospho-p90RSK [ Time Frame: 18 months ]Blood samples will be analysed for the level of phospho-p90RSK
- Level of transcript biomarker [ Time Frame: 18 months ]Blood samples will be analysed for the level of DUSP6
- Level of phospho-ERK [ Time Frame: 18 months ]Blood samples will be analysed for the level of phospho-ERK
- Level of total ERK [ Time Frame: 18 months ]Blood samples will be analysed for the level of total ERK
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
- Aged at least 18 years.
- Patient must have a documented activating alteration of the RAS-MAPK pathway.
- Histological or cytological confirmation of a solid tumour.
- Patients with hematological malignancies.
- Patient with solid tumors must have at least 1 lesion, not previously irradiated.
- Estimated life expectancy of minimum of 12 weeks.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Ability to swallow and retain oral medication.
Exclusion Criteria:
- Central nervous system metastatic disease, leptomeningeal disease, or metastatic cord compression.
- Prior ATG-017 administration in the present study.
- Prior treatment with an ERK1/2 inhibitor.
- Prior major surgery within 28 days of the first dose of study treatment or minor surgical procedures ≤7 days.
- Patients receiving unstable or increasing doses of corticosteroids.
- As judged by the investigator, any evidence of severe or uncontrolled systemic diseases.
- Active infection including hepatitis B, and/or hepatitis C.
- Known history of human immunodeficiency virus (HIV) infection.
-
Inadequate bone marrow reserve or organ function
-
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04305249
Contacts
| Contact: Shimin Sun Sun, M.D. | 021-23566665 | jasmine.sun@antengene.com | |
| Contact: Leng Julia, M.Sc | julia.leng@antengene.com |
Locations
| Australia, Victoria | |
| Peter MacCallum Cancer Centre | Recruiting |
| East Melbourne, Victoria, Australia, 3002 | |
| Principal Investigator: Ben Tran | |
| Principal Investigator: Jayesh Desai | |
| Austin Hospital | Recruiting |
| Heidelberg, Victoria, Australia, 3084 | |
| Contact: Hui Gan | |
| Principal Investigator: Hui Gan | |
| Alfred Hospital | Recruiting |
| Melbourne, Victoria, Australia, 3004 | |
| Contact: Mark Voskoboynik | |
| Principal Investigator: Mark Voskoboynik | |
| Australia | |
| Scientia Clinical Research | Recruiting |
| Randwick, Australia | |
| Contact: Charlotte Lemech | |
| Chris O'Brien Lifehouse | Recruiting |
| Sydney, Australia | |
| Contact: Lisa Horvath | |
Sponsors and Collaborators
Antengene Therapeutics Limited
Investigators
| Study Director: | Sai Lou, MD | Medical Monitor |
| Responsible Party: | Antengene Therapeutics Limited |
| ClinicalTrials.gov Identifier: | NCT04305249 |
| Other Study ID Numbers: |
ATG-017-001 |
| First Posted: | March 12, 2020 Key Record Dates |
| Last Update Posted: | August 4, 2022 |
| Last Verified: | June 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Neoplasms Hematologic Neoplasms Neoplasms by Site Hematologic Diseases |